Results 121 to 130 of about 45,236 (264)
Effect of allopurinol on phosphocreatine recovery and muscle function in older people with impaired physical function:a randomised controlled trial [PDF]
, 2020 Cavin, Ian +10 more
core +2 more sources
Drug-drug interactions in repeat prescriptions at village dispensaries (bereg) in Malta [PDF]
, 2013 Inappropriate treatments and drug-drug interactions (DDIs) are known to occur in settings where repeat prescriptions are issued. In view of this, a study was carried out to document any such problematic drug prescribing and propose changes that would
Bugeja, Anton
core
Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort [PDF]
, 2017 Gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Pérez Ruiz, Fernando
core +2 more sources
The conversion of 4-hydroxypyrazolo-[3,4-d]pyrimidine (allopurinol) into 4,6-dihydroxypyrazolo[3,4-d]pyrimidine (oxipurinol) in vivo in the absence of xanthine–oxygen oxidoreductase [PDF]
, 1969 R. A. Chalmers +4 more
openalex +1 more source
Opportunities and Challenges of Population Pharmacogenomics
Annals of Human Genetics, Volume 89, Issue 5, Page 384-397, September 2025.ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou +3 more
wiley +1 more source
Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes
Annals of Human Genetics, Volume 89, Issue 5, Page 398-405, September 2025.ABSTRACT Pharmacogenomics, the use of germline genomic data to guide prescription to improve effective and safer medication, holds promise as a clinical intervention. To date in most health systems, there has been limited uptake of pharmacogenomic testing confined to a few single drug–gene associations.
John Henry McDermott +3 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 438-448, August 2025.In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen +12 more
wiley +1 more source